1 / 35

Frontiers of knowledge at the crossroads between life sciences, I.T., engineering

Frontiers of knowledge at the crossroads between life sciences, I.T., engineering. An explosion of knowledge Large international genome sequencing programmes e.g. yeast 1996; arabidopsis 2000; listeria 2000; human 2001

blake
Download Presentation

Frontiers of knowledge at the crossroads between life sciences, I.T., engineering

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frontiers of knowledge at the crossroads between life sciences, I.T., engineering An explosion of knowledge • Large international genome sequencing programmes e.g. yeast 1996; arabidopsis 2000; listeria 2000; human 2001 • Bioinformatics: emergence of a new research field • From biosensors to nanobiotechnologies A wide range of applications • Gene therapy (for curing diseases of genetic origin) • Preventive medicine to encourage healthy ageing • Reappraisal of food production systems • Sustainable production of added value molecules • Monitoring biodiversity and eco-system dynamics

  2. 40 15 30 EBI Budget (M€) 10 20 EC Contribution (M€) MEuro Giga Bases DNA Data Base Growth 5 10 0 0 2000 2001 2002 2003 DNA Database Growth and Funding evolution of the European Bioinformatics Institute (EBI) Generating and exploiting knowledge • Develop a competitive bioinformatics infrastructure in collaboration with the European Investment Fund ACTION

  3. Anticipated impacts of technologies on way of life: 2002

  4. European attitudes to six applications of biotechnology

  5. Support and opposition for six applications of biotechnology in 15 countries

  6. THE POLITICAL DRIVE-1 “Towards a European research area” - COM 2000(6) Proposes better framework conditions to foster integration of research activities and coordinationof research and innovation policies Lisbon Summit - March 2000 Sets a strategic goal for Europe to become the most competitive and dynamic knowledge-based economy in the world

  7. THE POLITICAL DRIVE-2 Stockholm Summit - March 2001 Highlights the importance of research, entrepreneurship... Identifies biotechnology as a frontier technology … and requests the Commission, together with the Council, to examine measures required to utilise the full potential of biotechnology and strengthen the European biotechnology sector's competitiveness Commission Communication (COM/2002/27)- 23 January 2002 Life Sciences and Biotechnology: a Strategy for Europe. Policy orientations and a 30-point Action Plan.

  8. THE POLITICAL DRIVE-3 Barcelona Summit - March 2002 Calls for adoption of the 6th Framework Programme by June 2002, agrees that research spending in the EU should approach 3% GDP by 2010, with two thirds coming from business, stresses the importance of frontier technologies for future growth and welcomes the Commission's strategic vision for biotechnology and life sciences European Parliament Damiao Report - 23 October 2002 Endorses the Commission Strategy and Action Plan. Calls for lifting the GMO moratorium in order to stimulate research and innovation.

  9. THE POLITICAL DRIVE-4 Competitiveness Council Conclusions - 26 November 2002 Strongly endorses Commission’s Action Plan. Adopts Road Map, setting specific objectives for Community and Member States levels. Timetable for Implementation. Commission Communication of March 2003 Progress report and future orientations Commission staff working paper on Commission actions

  10. 2 1 GOVERNING Life Sciences and Biotechnology HARVESTING the POTENTIAL 4 3 Implementation and COHERENCE across policies, sectors and actors RESPONDING to GLOBAL challenges The Life Sciences and Biotechnology : a Strategy for EuropeAction Plan EC + EP + COUNCIL + MEMBER STATES + REGIONS + PRIVATE SECTOR + ACADEMIA + PROFESSIONAL ASSOCIATIONS + CIVIL SOCIETY + EIB + EFSA + EMEA + EGE ... Who? How?

  11. 1. Harvesting the Potential The resource Base investing in people generating and exploiting knowledge intellectual property protection capital base Networking Europe’s Biotechnology Communities A pro-active role for public authorities 2. Governing Life Sciences and Biotechnology Societal scrutiny and dialogue Developing Life Sciences and Biotechnology in harmony with ethical values and social goals Demand-driven applications through informed choice Confidence in science-based regulatory oversight A European Strategy for Life Sciences and Biotechnology: The Action Plan - COM (2002) 27 3. Responding to global challenge • A European agenda for international collaboration • Europe’s responsibilities towards the developing world 4. Implementation and coherence across policies, sectors and actors

  12. Life Sciences and Biotechnology StrategyAction 2b Investing in Researchers CHALLENGES • Brain drain of scientists and entrepreneurs • Lack of specialised workforce in industry ACTIONS • Develop and train a skilled workforce • Promote continuing education • Attract scientists to Europe 1 580 M€ for human resources and mobility in FP6 (from 858 M€ in FP5) with emphasis on return grants

  13. Life Sciences and Biotechnology StrategyAction 3: ResearchLife Sciences, Genomics and Biotechnology for Health • Advanced Genomics and its applications for health • Fundamental knowledge and basic tools for functional genomics • in all organisms • (Structural genomics; proteomics; comparative genomics; bioinformatics; • Multidisciplinary genomics approaches to basic biological processes) • Application of knowledge and technologies in the field of • genomics and biotechnology for health • (Industrial platforms; support to start-up companies) • Combating major diseases • Application-oriented approach to medical genomics knowledge • (Cardiovascular disease, diabetes and rare diseases ; resistance to • antibiotics ; Studying the brain and combating diseases of the nervous • system ; Studying human development and the ageing process) • Broader biomedical approach • (cancer, poverty-related infectious diseases) Life Sciences, Genomics & biotechnology for health

  14. Structural proteomics in Europe • 17 Partners: leaders in the field (10 countries: UK, FR, IT, DE, PT, SE, DK, NL, IS, HE) • EC contribution 13.7 m€ Goals • Development of technological platforms permitting high throughput structure determination • Determining the 3D structure of +500 medically relevant proteins • Establishment of a robust, interactive, and open network of European centres of excellence, integrating national, international efforts - academic labs and biotech SMEs. • Provision of the necessary training environments for young scientists and technicians

  15. Biological Targets viral, bacteria, cancer, etc Technical Platforms crystallisation, X-Ray, NMR ... Scientific Advisory Board Biotech SME Biotech SME Biotech SME Biotech SME Biotech SME Biotech SME Structural Proteomics in Europe Training Research Networking Executive Committee • develop technologies for high throughput 3D structure • determination of +500 medically relevant proteins

  16. Life Sciences and Biotechnology Strategy Action 3 Research : Food Quality and Safety Integrating European Research Priority Thematic Areas • Epidemiology of food related diseases • Impact of food (including GMOs) on health • Traceability processes (including GMOs) • Methods of Analysis/Detection/Control • Safer and environmentally friendly production/processing methods • Impact of animal feed on health • Environmental health risks Citizens & governance in the knowledge society Food Quality and Safety

  17. Science Platform Scientific Audience Industry Platform Commercial Audience Consumer Platform Consumer Audience Cluster of research projects on the development of probiotic foods Basic mechanisms Research tools FP5 Cluster Coordination PROEUHEALTH Total Cost: 17 M€ EC Contribution: 12 M€ Partners: 64 Technology aspects Health effects

  18. Life Sciences and Biotechnology Strategy - Action 3: Research Generating and exploiting knowledgeOpportunities for SMEs in FP6 • Within many of the seven thematic priorities 15% of the budget is reserved for SMEs! • Specific measures for SMEs: CRAFT and Collective Research~ €100 mio will go to life science related projects • Support for hosting post-docs: Industry fellowships The budget for mobility grants has almost doubled from FP5 to FP6!

  19. 13 % Biotech 5 % Overall EPO patenting annual growth rate (1990-1999) Life Sciences and Biotechnology StrategyAction 5 : Intellectual Property Protection CHALLENGES • Need for an effective, affordable and accessible European intellectual property protection system ACTIONS • Adoption of a Community Patent Regulation • Transposition of the Biotechnology Patent Directive • Awareness and training in strategic use of IPR

  20. Life Sciences and Biotechnology StrategyAction 6 :Capital base The Innovation 2000 Initiative of the European Investment Bank € 12-15 billion for lending and € 1 billion for developing VC operations in the areas: • development of SMEs and entrepreneurship • diffusion of innovation • research and development • ICT networks • human capital formation The EIB and the Life Science programs are working closely together to identify financing opportunities, in particular for biotech SMEs

  21. Life Sciences and Biotechnology StrategyAction 7: Capital BaseBiotechnology & Finance Forum « Biotechnology & Finance Forum » was set up by the Commission and EASD (European Association of Securities Dealers) in 1997 to ensure the mobilization and networking of the European research, industry and finance stakeholders in biotechnology • 4 pan European conferences in Brussels (98), Lyon (99), Cambridge (00), Paris (01) (next: Munich Feb 03) • support for setting up biotech companies and networking of biotech clusters • inclusion of major stakeholders into the BFF advisory board 2002: EuropaBio, EFB, EIB, EIF, EVCA, APCIMS/EASD

  22. 1879 Biotechnology companies in Europe in 2001(US 1457)-Tripled in number in 5 years Life Sciences and Biotechnology Strategy Action 8a Networking

  23. Life Sciences and Biotechnology Strategy Action 9b :Networking “Bio-entrepreneurship: Networking of Biotechnology Clusters in Europe” • Biotech start-ups are not “regional companies”. They have needs - scientific, financial, market, management - requiring European assistance. • Need for networking of bioclusters across Europe (e.g. exchange of best practise, skills, critical mass) - if successful entrepreneurship in biotechnology is to be promoted rapidly and efficiently.

  24. BIOVALLEY® in upper rhine region: (Northwest Switzerland, CH + South Baden, DE + Alsace, FR) MEDICON VALLEY:Öresund region (Southern part of Sweden, SE + Greater Copenhagen, DK) EUREGIO: Meuse-Rhine regionMaastricht, NL + Aachen, DE + Liège, BE Life Sciences and Biotechnology StrategyAction 9bNetworkingTrans-national biotechnology clusters: 3 examples

  25. Life Sciences and Biotechnology StrategyAction 13:Societal scrutiny and dialogue Challenges:Enhancing public understanding and perceptions of life sciences and biotechnology. Actions:Support science communication and dialogue with the public. Monitor public perceptions : Eurobarometer, focus groups.Encourage civil society involvement: support European citizen networks. Stakeholders Scientists Industry Civil Society Interest Groups European Group of Life Scientists

  26. CONSENSUS WORKSHOPSIdentifying and defining consensus on key food issues Consensus forming • Bridging the gap between consumers, scientists and stakeholders from the food chain through three international workshops, running from 2002-3. • The workshops cover the following themes: • Food safety (June 2002) • Novel foods (February 2003) • Nutrition (July 2003) • The presentations and outcomes of the workshops are published on the consensus workshop website: http://www.consensusworkshops.org/

  27. BIO-TEACH-WORK Continuing education for EU biology teachers Popularisation of life sciences - Education • The Bio-Teach-Work project aims to make available the skills and resources of research scientists to the European Union’s biology teachers. • Three main activities: • ·Workshops offering both theoretical and practical training for biology teachers • ·A training programme for scientists and teachers – developing new resources; sharing best practice • Creating a resource centre and archive for teaching materials • http://www.embo.org/projects/scisoc/ceebt/index.html

  28. GMO RES COM Biosafety research communication Consensus forming - Support to policies • The three-year project aims at improving communication and public dialogue on biosafety by: • ·Supporting a new journal on the biosafety of GMOs • ·Supporting a series of international symposia on the safety of GMOs • ·Creating a web-based, publicly accessible database on GMO safety research • Issues being addressed by this accompanying measure: • ·Meeting the need for a coordinated research effort • ·Efficient exchange of information to scientists and the public

  29. SCIENCE GENERATION Bridging the gap between the science and the citizens Popularisation of life sciences - Public dialogue • Towards a EU network of citizens • for a participative governance of life sciences • bringing together students, teachers, parents, scientists, economists, lawyers, policy makers and other stakeholders, • ·Aims to improve communication,education, public awareness and consideration of public perceptionsrelating to biosciences and society • ·Enabling ordinary citizens to become involved and proactive in biosciences and the implications that can affect their future • Pilote EU experience active in three countries: France, Italy and Sweden http://www.science-generation.com/

  30. Life Sciences and Biotechnology Strategy Action 14:Harmony with ethical values and societal goals Challenges: To develop life sciences and biotechnology in a responsible manner: in harmony with ethical values and societal goals, while respecting cultural pluralism. Topics: Xenotransplantation Human embryonic stem cells Biobanks Gene testing Actions: Research into socio-economic and ethical issues and development of assessment criteria. Consider ethical, social and legal aspects of new developments. Attempt consensus on ethical guidelines.

  31. Bio-T-Ethics Biotechnology ethics – a vital discipline for the 21st century Education - Ethical principles A strategic initiative to contribute research efforts and education in biotechnology ethics. • Foremost authorities on biotechnology ethics from 11 countries , in consultation with stakeholders, will: • · Define aspects of the biology-industry interface requiring ethical expertise • ·Organise studies to improve communications and application of ethics • ·Find ways to transfer the ethics research into education • Organise pillote courses on biotechnology ethics • … towards a European School for Biotechnology Ethics

  32. FNIBI Teaching ethics Training - Ethical principles • Consideration to ethics in the life sciences research and education is a key principle of the EU research policies • This measure runs workshops to train life scientists to integrate ethics into their courses and laboratories • ·A EU-US joint effort by the FLAD/NSF International Bioethics Institute • Three courses run to date, with teachers from the USA and Europe • Use of ‘active learning’ methods

  33. DELIVERABLES FOR SOCIETY RESEARCH DEVELOPMENT REGULATION Success will depend on mobilisation of all actors Ethical Bodies Academia Regions Private Sector European Investment Bank Civil Society Member States Parliament Commission

  34. The European Group on Life Sciences Members 2002 : V. De Lorenzo (E) (Chair), D. Burke (UK) , P. Cunningham (IRL), L. Kovac (SK), P. Kourilsky (F), C. Nüsslein-Volhard (D), A. Mc Laren (UK), N Rosentahl (USA- I), J. van Bemmel (NL), M. van Montagu (B), L. Santi (I), H. Wigzell (S), E-L Winnacker (D) • Established by Commissioner P. Busquin in April 2000, with the mandate of: • providing high level advice on the current situation and foreseeable developments in the field of life sciences • supporting broad science-communication strategies, particularly by organisinga Life Sciences Discussion Platform http://europa.eu.int/comm/research/life-sciences/egls/index_en.html

  35. GENETICS AND THE FUTURE OF EUROPE STEM CELLS: THERAPIES FOR THE FUTURE? TOWARDS SUSTAINABLE AGRICULTURE FOR DEVELOPING COUNTRIES: OPTIONS FROM LIFE SCIENCES AND BIOTECHNOLOGY EGLS LIFE SCIENCES DISCUSSION PLATFORMS SCIENTISTS, INDUSTRY, CIVIL SOCIETY, YOUTH, INTEREST GROUPS, MEDIA, POLICY MAKERS... • Multiple Stakeholders • Reciprocal Information • Questions, Debate

More Related